Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02NMO
|
|||
| Former ID |
DPR000047
|
|||
| Drug Name |
FR-79620
|
|||
| Synonyms |
3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y] | Preclinical | [1] | |
| Eating disorder [ICD-11: 6B82] | Preclinical | [1] | ||
| Obesity [ICD-11: 5B81; ICD-10: E66] | Preclinical | [1] | ||
| Company |
Fujisawa
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H13N3
|
|||
| Canonical SMILES |
CC1=C(N=C(N1)C2=CC=CC=C2)C3=CN=CC=C3
|
|||
| InChI |
1S/C15H13N3/c1-11-14(13-8-5-9-16-10-13)18-15(17-11)12-6-3-2-4-7-12/h2-10H,1H3,(H,17,18)
|
|||
| InChIKey |
CAQAIFUDUGDPFB-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuropeptide Y receptor type 5 (NPY5R) | Target Info | Antagonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.